Dear ladies and gentlemen, welcome to the conference call of Medacta Group SA. At our customers' request, this conference will be recorded. As a reminder, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If any participant has difficulties during the conference, please press star and zero on your telephone for an operator's assistance. May I now hand over to Mr. Siccardi, who will lead you through this conference. Please go ahead, sir. Thank you. Thank you very much. Welcome to this H1 2021 preliminary and audited top-line figures call. We will go through the highlights of the first semester. With me there is Corrado Farsetta, our CFO, and Gianna La Rana. In case there are question after the presentation, we're going to have the usual Q&A session. Starting with the highlights of this first semester, we have to say we have been very pleased with the revenue increase. We reached EUR 177.5 million, which is 35.4% at constant currency versus last year. We all have to remember that last year, semester was of course, highly impacted by COVID, which explains as well those very high percentages partially. The growth was driven by a significant carryover and new customer acquisition. This was coupled with a faster than anticipated normalization of surgery activities, especially I would say, in Europe and in the U.S. The carryover and customer acquisition was very much linked to the last year H2 activity in medical education. I'm very, very pleased that we finally see the results of our last year effort. The contribution in terms of growth was coming from all our business lines and from all geographies as we will see in a few slides. It was supported as well by, again, a significant amount of new products registration across all our business lines, hip, knees, shoulders, spine, and sports medicine in several geographies, mainly CE marking and FDA clearances, but as well, some very key products cleared in Australia and in Japan. We managed to continue our marketing and education activities, which is of paramount importance to continue to fill our pipeline of new customer acquisition. Since June, we have restarted our international traveling activity and some of the third-party congresses have restarted with an acceleration expected in H2 2021, provided the COVID restriction will not be lifted again or increased. Last pillar of growth, which is extremely relevant, is hiring and expansion of our sales force, continued as planned across all geographies at different pace as well for the different business lines. Moving to the revenue bridge by product line. We have been able to grow not only the fast-growing portion of our business, which are typically extremities and spine, but we managed to have a very strong growth as well in hips with a 30%+ growth rate versus H1, and even a stronger acceleration in knees with a 38.4%. This was associated with our most recent strategy in hips with AMIS and as well the expansion in our revision product portfolio. On the knee side with our GMK Sphere platform and our personalized solutions. Within the extremities, we continue to expand our platform, sales force, and personalized solutions as well. Finally, spine, which is, again, driven by a product range expansion, new technologies, and sales force expansion. This was extremely successful in H1. We're very pleased with all the business line contributing significantly to the top-line performance. If we analyze the revenues by geography, we have seen a very strong contribution from Europe. Once again, Europe was the most affected region last year, so it was to be expected, a very good bounce back in Europe. U.S. was actually even stronger with a 44.3%. Some slow months last year, but still a very, very good growth rate across all the lines. Asia-Pacific, we were all particularly pleased because, Asia-Pacific was not as impacted as all the other areas last year. Top-line revenue was mainly driven, of course, by Australia and followed by Japanese colleagues. Finally, the rest of the world that went back on track on the growth path with almost 50% growth, of course, comparing with a very weak H1 last year. Very important factor on the next slide. A quick update on the NextAR deployment. Our augmented reality surgical platform gained very important clearances in Europe with CE marking of our knee, shoulder, and spine applications in the last weeks of May. This has translated in some very good introduction. The first cases in Europe are going extremely well, both for knees, shoulder, and spine. A lot of interest across our customer base. Shoulder application was cleared as well by the FDA in the U.S., where our knee application was already cleared in 2020. The NextAR is really leveraging our experience, with the MySolutions Ecosystem, which is exactly the same 3D planning and platform and data-sharing solution we have been using now for several years for our other personalized medicine application, the PSI, the personalized solution. This is drastically increasing our holistic approach to personalized medicine, which has a very strong potential to improve surgical accuracy and improve, at the same time, the economical impact of those solution in the healthcare system. This is particularly true for our surgical platform, which has a very limited upfront capital investment compared to our main competitors in the market. Another very important feature is that we have, in one solution, application not only for knees or hips, but as well for shoulder and spine. This is particularly interesting in certain markets, definitely in the ASC market in the U.S., but as well in markets like Europe or Japan, where volumes are potentially smaller, or reimbursement opportunities are completely different from the U.S. market. Based on the strong activity and strong performance of H1, we have been able to review our 2021 outlook, and we have updated our guidance in terms of top line, increasing it to a range from EUR 355 million- EUR 375 million at constant currency. While we left our EBITDA margin, in terms of guidance, in line with our 2020. All those assumptions are based on hoping that the COVID-19 pandemic will allow us to continue to work at least in the same way we were able to work in H1. Numbers are not giving us a very good night to sleep, but we really hope that September, October will not come with additional restrictions linked to COVID. This was a short update on our half-year top-line figures. As you know, we will have additional information on profitability in September, 10th of September. I think we would be more than happy to go through any Q&A you might have. Thank you very much. Dear ladies and gentlemen, now we will begin our question and answer session. If you are on the conference call and have a question for our speakers, please dial zero and one on your telephone keypad now to enter the queue. Once your name has been announced, you can ask a question. If you find your question is answered before it's your turn to speak, you can dial zero and two to cancel your question. If you are using speaker equipment today, please mute the handset before making a selection. If you participate via the audio webcast, you can send a question via the Q&A function over the webcast by pressing the question mark button. At the end of the hour, our unanswered questions can be addressed to investor.relations@medacta.ch. One moment, please, for the first question. We have our first question. It's from David Adlington, JP Morgan. The line is now open for you. Hey, guys. Thanks for taking the question. Yeah, just on the profitability side, I know you might not want to make too much of comments given in reporting those numbers later on, but given the sales beat and the upgraded sales guidance, obviously you decided to keep the margin guidance unchanged. Just wonder which areas you're investing in more than you expected at the beginning of the year, and maybe some further comment as well on how the investments are going would be great, please. Thank you, David. We have a very good momentum in H1. We are extremely keen in keeping this momentum. Moving forward, we see quite a lot of opportunities as well in the market in terms of hiring sales force in different regions and for different product lines. We want to capitalize on those opportunities. I would say mainly in the sales and marketing expansion opportunities. It is as well not 100% clear in terms of third-party events, how many of those events will actually take place, how many will not, and this, of course, is outside of our control. We are currently budgeting to participate, let's say, in a more or less normal way to those third-party events. This might materialize or not, but at the moment, we are budgeting for both an expansion in sales and marketing and a normalization of our marketing activity in terms of third-party events, while, of course, we continue to invest in medical education, I would say, at the same pace or slightly higher, compared to H1. Perfect. Thank you. Our next question is by Aisyah Noor, Morgan Stanley. The line is now open for you. Oh, great. Thank you. I have two questions, please. The first one is on surgeon recruitment. Where are you at the moment with progress on the surgeons recruited for the year, and how does this compare to the annual rate pre-COVID levels? The second question is just a quick one on the exit rate you saw in June and perhaps in July. If you could provide that would be helpful. Thank you. Yeah. Surgeon recruitment went back to normal already at the beginning of the year. In certain areas, we even actually accelerated compared to original plans. We have changed quite a lot in terms of medical education, as we highlighted several times, due to the experience we made during COVID and as well somehow linked to the current limitations in international traveling. We have made quite a lot of regional learning centers, surgeon to surgeon visitations at national level rather than international. This has a slightly lower cost at the end and a much faster conversion rate, so the time to convert a surgeon has shortened. In terms of overall number of surgeons, we are perfectly in line with our plans or slightly ahead. In terms of acceleration, June has been a very good month. Of course, we're not guiding month-on-month, but is very much in line with our non-COVID-related budget or numbers. We will not, of course, comment on July or expectation moving forward on top of the guidance update we provided, but we are confident that if no restrictions are coming, we would be able to deliver a very good H2 as well. Maybe an important factor we did not comment yet is the source of growth. We mentioned it's very much coming from carryover business, existing business, of course, and new customers. We did not see or we did not count yet a significant pent-up demand recovery. This might be an additional surprise on which we are not really betting, but it could come on top of what we are expecting for H2 at the moment. Great. Thank you. Our next question is by Chris Gretler, Credit Suisse. The line is now also open for you. Thank you, operator. Good afternoon, Francesco, Corrado. Hi, Chris. Gianna. Hi. Hi, Chris. Just a question on the upgraded guidance, and relative to your original plans. Maybe could you break out what, in particular, in terms of geographies and business lines are outperforming your expectation, or is it just broad-based? Yeah. I would say in general is a faster normalization in Europe. Even in the, let's say, COVID months of, for example, April in France, we did not see the same drops we did see in March or in October last year. This, of course, increased our level of activity even in those, let's say, difficult months. This was mainly the dynamic in Europe. U.S. normalized pretty quickly. The second quarter was basically back to normal in the vast majority of the U.S. territories. What really surprised us and really are ahead of our expectation is the performance in Asia Pacific, which is, of course, more than welcome, as we all know, the pricing in that segment is stronger than in the other geographies. This will help us, not only in terms of top line, but potentially if it stays like this at the end of the year, maybe potentially on the profitability side. The over-performance in the Asia-Pacific, Australia in particular, was a very good surprise. Okay. Wanted to ask on that. Anyway, no, I will come back. The other question I had was on the extremities business. Could you indicate, kind of how significant is actually the sports med business already, or is it basically majority is still kind of, shoulder or in here, the large majority, or how is that? Large majority. Yeah. Large majority is shoulder. Sports medicine is in the final stage of having many products in limited market release. We will start to invest in expanding our sports medicine products in the different key geographies in basically end of this year, beginning of following year. At the moment, top line, when we talk about extremities is shoulder. Okay. Yeah. You know, the other question came back on the outperformance relative to expectation and now subsequent, is there already kind of an indication that some capacities basically become a bit more constrained? You mentioned Australia and it looks like they are going into, at least in some states, back to lockdown mode, so do you already see something from these latest, kind of spike in infection rates? In general, is the business still very kind of diverse in terms now of momentum? Again, very differently from the last lockdowns in Australia, we did not see a negative impact yet on our daily business. As you know, there are lockdowns in place at the moment, both in Melbourne and especially in Sydney. They are very different from the previous lockdowns where most of the activities were impacted. Some hospitals have limited, again, surgical theater time for surgeons, but much less than in the previous lockdown. So far so good, and of course, we keep our fingers crossed and we will see. It's slightly different than what we have experienced in the last lockdowns in Australia. Japan is a big question mark. The Olympics, the numbers, but they have never been really very strongly impacted by COVID, and when it does, it usually picks up again relatively quickly. Different experience, but so far the existing lockdowns did not really impact it negatively in a significant way. Maybe a few hundred thousand here and there, but that's it. Okay. Maybe the last question, just now, going back to salesforce expansion, and maybe could you give us an update on the latest priorities you have there at the moment? No, yeah, we are expanding across all the product lines, and of course, in a market like Europe, we would probably prioritize more the less mature segment like spine and shoulder in the near future, sports medicine. Of course, we take every opportunity to improve our territory coverage in hip and knees as well. In the U.S., it's definitely across all the product lines. We actually have a delegation of U.S. colleagues here in Switzerland to discuss the acceleration of H2 across all the business lines, both direct and through collaboration with distributor agents. Australia and Japan, mainly in hip and knees in Australia and across all the line in Japan. Depending on the key areas, there are some focus, but whenever we see opportunities and talents available, we go for it. Okay. Thank you. I appreciate your comment. Thank you. As a reminder, if you want to ask a question, please press zero and one on your telephone to ask a question. Our next question is by Daniel Jelovcan. The line is now open for you. Yes, it's Daniel Jelovcan from Mirabaud. Just to understand it a bit better, I compared your first half sales growth to the first half sales growth of 2019, and my calculation is that you are up 17%. Pre-pandemic, which I believe is a very strong result. Is it fair to say that this is your true underlying growth, or do I do some miscalculation with backlog pent up? As far as I remember from the last calls, you explained that you always have a kind of backlog irrespective of COVID or not, because if I have a hip surgery, I have to wait six months or whatever anyway. Is the backlog, does that still play a role or is it mostly over? That's the question. Yeah. I would say we did not see a significant contribution from, let's say, pent-up demand, meaning with the pent-up demand, existing customers that would be able to do much more than what is usually their baseline. It was very different last summer, where we have seen customers doing 120%, 130%, 140%. In few weeks or in few months, they were able to recover one or two months of lockdown effect. In H1, we did not see that contribution almost anywhere. The growth you mentioned is a very good growth. I'm very happy with it. It is probably our base intrinsic growth, with the exception of some extraordinary contribution provided by some new countries like Saudi Arabia, other distributors that did start in H1. As you can see, the rest of the world bucket is not a very large bucket. This is maybe the only exceptional item that would have a spike rather than a constant growth. I hope I answer your question in this way. Yeah, very clear. Thanks. Thank you. There are no further questions, so I hand back to you. Thank you very much. I don't know, Corrado, if you wanted to further clarify any additional item we highlighted in the last few weeks with the ad doc release, et cetera. If there are no specific question, I suppose it's fine, just for you maybe. Yes. I think that the only comment we can do maybe to make a bit more clear about the accruals on the MicroPort, which was finally and completely settled. As it was disclosed in our annual report, there was already a provision, already recognized in our accounts for EUR 10,300,000. Basically, given the size of the settlement, we have a limited effect on the accounts that we're going to publish in September, with an additional accrual in the region of $5 million, something more than $5 million. Basically, that number will be adjusted as usual, but the additional impact on our accounts would be limited to less than $6 million. I think that there will be full disclosure in the numbers, but that is something that can be worth for the investor to be known. Thank you, Corrado. I would pass it over to the operator if there is any additional question. Otherwise, I would like to thank you all for your time and attention. Of course, we are available for any additional question with our Investor Relations. At the moment, there are no further questions. Thank you very much, Dan. I look forward to speak with all of you soon again. Thank you very much to all. Thank you. Ladies and gentlemen, thank you for your attendance. This call has been concluded. You may disconnect.